UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

___________

FORM 8-K

___________

CURRENT REPORT

~~Pursuant~~PURSUANT toTO ~~Section~~SECTION 13 orOR 15(d) ofOF ~~the Securities Exchange Act of 1934~~THE

~~Date~~SECURITIES ofEXCHANGE ~~Report~~ACT ~~(Date~~OF ~~of earliest event reported): September 15, 2015~~1934

~~PANACEA~~Date ~~GLOBAL~~of Report (Date of earliest event reported): June 15, ~~INC.~~2016

Panacea Global, Inc.

(Exact name of registrant as specified in its charter)

Nevada	000-30424	33-0680443
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(IRS Employer Identification No.)
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

330 Highway #7 East, Suite #502, Richmond Hill Ontario, Canada		L4B3P8
(Address of principal executive offices)		(Zip Code)

330 Highway #7, Suite 502, Richmond Hill

~~Registrant’s~~Ontario, ~~telephone number~~Canada, ~~including area code: (416) 450-6414~~L4B3P8

~~Not Applicable~~ (~~Former~~Address ~~name~~of orprincipal ~~former~~executive ~~address,~~offices) if(Zip ~~changed since last report~~Code)

~~Check the appropriate box below if the Form 8~~416-~~K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:~~450-6414

~~[ ]~~(Registrant’s telephone number, including area code)

~~Written~~Check ~~communications~~the ~~pursuant~~appropriate box below if the Form 8-K filing is intended to ~~Rule~~simultaneously ~~425~~satisfy the filing obligation of the registrant under any of the ~~Securities~~following ~~Act~~provisions (17see ~~CFR~~General ~~230~~Instruction A.~~425~~2. below):

~~[ ]~~o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)

[ ]

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))

[ ]

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

Item 45.0102 ~~Changes~~Departure inof ~~Registrant’s~~Directors ~~Certifying~~or ~~Accountant~~Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

~~Dismissal~~On June 15, the Board of ~~Previous~~Directors ~~Independent~~(the ~~Registered~~“Board”) ~~Public~~appointed ~~Accounting~~Yuri ~~Firm~~Lawryshyn and Dr. Chandra Panchal to the Board of Panacea Global, Inc. (the “Company).

On ~~September~~June 1516, ~~2015~~2016, the ~~Board~~Company received letters of ~~Directors~~resignations from Mahmood Moshiri, Zahra Shariat and Binnay Sethi, from the Board of ~~Panacea~~the ~~Global~~Company, ~~Inc~~effectively immediately. The (resignations were not a result of any disagreement with the “Company”) ~~dismissed~~on ~~GBH~~any ~~CPAs,~~matter PCrelating ~~(“GBH”)~~to asthe ~~its~~Company’s ~~independent~~operations, ~~registered~~policies ~~public~~(including accounting ~~firm.~~or financial policies) or practices.

~~GBH~~On ~~was~~June ~~engaged~~16, ~~as our independent registered public accounting firm on September 5~~2016, ~~2014. They did not issue any reports on~~ the ~~audited financial statements of the~~ Company ~~for~~received ~~any~~a ~~fiscal~~letter ~~year.~~of ~~During~~resignation ~~the~~from ~~Company’s~~Mahmood ~~two~~Moshiri ~~most~~as ~~recent~~Chief ~~fiscal~~Executive ~~years~~Officer, ~~the~~President ~~subsequent interim periods thereto,~~ and ~~through~~Chief ~~September~~Financial ~~15,~~Officer ~~2015, except as described below, there were no disagreements (as defined in Item 304~~ of ~~Regulation~~the ~~S-K) with GBH on any matter of accounting principles or practices~~Company, ~~financial~~effective ~~statement~~immediately. Mr. ~~disclosure,~~Moshiri’s orresignation ~~auditing~~was ~~scope or procedure, which disagreements, if~~ not ~~resolved~~a toresult ~~the satisfaction~~ of ~~GBH,~~any ~~would~~disagreement ~~have caused it to make reference in connection~~ with ~~its~~the ~~opinion~~Company toon ~~the~~any ~~subject~~ matter ofrelating ~~the disagreement except for a disagreement related~~ to ~~a determination of~~ the appropriate valuation of certain intangible assets related to the fiscal year ended December 31, 2014 for which the registrant was not able to resolve to the satisfaction of GBH such valuation for financial statement disclosure. Further, during the Company’s ~~two most recent fiscal years~~operations, ~~the~~policies ~~subsequent interim periods thereto, and through September 15, 2015, there were no reportable events~~ (asincluding ~~defined~~accounting inor ~~Item~~financial ~~304(a~~policies)~~(1)(v)~~ ofor ~~Regulation S-K) except as described above~~practices. Management and members of the Board of Directors discussed the nature of the disagreement with GBH prior to their dismissal and was unable to resolve the matter to the satisfaction of GBH. The registrant has authorized GBH to respond fully to the inquiries of the successor auditor concerning the subject matter of such disagreement.

WeOn ~~furnished~~June ~~GBH with a copy of this disclosure on September~~ 17, ~~2015~~2016, ~~providing GBH with~~ the ~~opportunity~~Board toappointed ~~furnish~~Yuri ~~the~~Lawryshyn ~~Company~~as ~~with~~interim aChief ~~letter~~Executive ~~addressed~~Officer ~~to the Securities and Exchange Commission (the “SEC”) stating whether it agrees with the statements made by us herein in response to Item 304(a)~~ of ~~Regulation S-K and, if not, stating~~ the ~~respect in which it does not agree~~Company. ~~A copy of GBH’s letter to the SEC is filed as Exhibit 16.1 to this report.~~

~~Engagement~~On ofJune ~~New~~17, ~~Independent~~2016, ~~Registered~~the ~~Public~~Board ~~Accounting~~appointed ~~Firm~~David Sohi as interim Chief Financial Officer of the Company.

On ~~September~~June 1517, ~~2015~~2016, the Board ofappointed ~~Directors~~Aras ofAzadian ~~the Company engaged L J Soldinger Associates, LLC (“Soldinger”)~~ as ~~our~~Chief ~~independent~~Operating ~~registered~~Officer ~~public~~of ~~accounting~~the ~~firm~~Company.

~~During~~A ~~the~~brief ~~years~~description ~~ended~~of ~~December 31, 2014, and 2013, and~~ the ~~subsequent~~background ~~interim~~experience ~~periods through September 15, 2015, neither the Company nor anyone acting on its behalf consulted Soldinger with respect to (i) the application~~ of ~~accounting~~Yuri ~~principles~~Lawryshyn ~~to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company’s financial statements,~~ and ~~neither~~Dr. aChandra ~~written~~Panchal ~~report~~is ~~nor oral advice was provided to the Company that Soldinger concluded was an important factor considered by the Company in reaching a decision~~ as to the accounting, auditing or financial reporting issues; or (ii) any matter that was the subject of a disagreement or a reportable event set forth in Item 304(a)(1)(iv) and (v), respectively, of Regulation S-K.follows:

~~Item~~YURI ~~9.01 Financial Statements and Exhibits.~~LAWRYSHYN, 50

After completing his Ph.D. in 1997, specializing in computational fluid dynamics (dCFD) ~~Exhibits: The~~, ~~following~~Dr. ~~exhibits~~Lawryshyn ~~are~~joined ~~filed~~the asResearch ~~part~~and Technology Centre of ~~this~~Abitibi-Price, ~~report:~~where he utilized his CFD expertise to develop a patented process equipment technology.

Exhibit No.		Description
16.1		Letter from GBH CPAs, PC.

In 1998 he joined Trojan Technologies Inc. where he established a CFD practice and led the development of the award winning SWIFT™ UV disinfection product line for municipal drinking water treatment. During this time, Dr. Lawryshyn was instrumental in developing an aspect of UV disinfection theory which plays a key component in current regulatory and industry best practices. In 2001, Dr. Lawryshyn took on the role of Core Sciences Manager and then Corporate Scientist. During this time, six patents were filed under his leadership. In 2002, Dr. Lawryshyn became Market Manager for the Wastewater Arena at Trojan where he was responsible for Trojan’s largest business arena, with annual revenues of approximately $60 to $70 million. In 2005, Dr. Lawryshyn moved to Europe as Trojan’s Technical Sales Manager where he developed business and marketing strategies for the region, leading to a significant increase in Trojan’s market share and gross margins in Europe.

~~Pursuant~~In late 2006, Dr. Lawryshyn resigned from Trojan to pursue an academic career. He joined the ~~requirements~~Faculty of ~~the~~Engineering ~~Securities~~at ~~Exchange~~the ~~Act~~University of ~~1934~~Toronto in 2007 as an Assistant Professor, specializing in applying financial engineering principles for the ~~Registrant~~valuation ~~has~~of ~~duly~~real ~~caused~~assets/projects, ~~this~~with ~~Current~~specific ~~Report~~emphasis onin ~~Form~~the ~~8-K~~development of practical approaches to bereal ~~signed~~option onvaluation ~~its~~and ~~behalf~~strategic bydecision making; and is currently an Associate Professor in the ~~undersigned~~Faculty. ~~hereunto~~Dr. ~~duly~~Lawryshyn ~~authorized~~continues to consult in both numerical modelling, and financial analysis and strategy.

Dr. Lawryshyn received a BASc and MASc from the University of Toronto in Mechanical Engineering, a PhD from the Department of Chemical Engineering and Applied Chemistry at the University of Toronto, an MBA from the Richard Ivey School of Business (University of Western Ontario) and a Financial Engineering Diploma from the Schulich School of Business (York University). Dr. Lawryshyn holds 7 patents, with two more recently applied for, has over 25 peer reviewed publications and over 60 conference papers / abstracts.

DR. CHANDRA PANCHAL, 67

Chandra Panchal obtained a B.Sc. (1972) and a M.Sc., in Molecular Biology (1974) from the University of Toronto, and a Ph.D., in Biochemical Engineering from the University of Western Ontario (1979).

Dr. Panchal is presently Chairmant & CEO at Axcelon Biopolymers Corporation, of London, Ontario, and Managing Director of Panford Investment Corp of Montreal. From 1989-1999 he was Co-founder, President, and CEO of Procyon Biopharma Inc., and from1999-2006 he was Chief Scientific Officer and Senior Executive VP.

From 2006 to 2008 he was Executive VP, Business Development, Licensing & Intellectual Property, at Ambrilia Biopharma Inc., which was a merger between Procyon and Cellpep Inc., of France. Prior to co-founding Procyon, Dr. Panchal was a senior scientist/group leader supervising activities related to yeast genetics, fermentation and product development at John Labatt Ltd., a multinational food and beverage company. Dr. Panchal has authored over 55 scientific papers and has edited a book entitled Yeast Strain Selection, published by Marcel Dekker.

Dr. Panchal has been on the editorial board of the Canadian Journal of Microbiology and is a co-inventor in respect of several patents in oncology, diagnostics and industrial microbiology. Dr. Panchal is an Adjunct Professor in Chemical and Biochemical Engineering at the University of Western Ontario.

He currently sits on the Boards of Canadian Oil Recovery and Remediation Inc., (CORRE; TSX.V:CVR), AC Simonds & Sons (OTC.BB:ACSX) and several private companies.

Family Relationships

No family relationship has ever existed between any director, executive officer of the Company, and any person contemplated to become such.

Related Party Transactions

There are no related party transactions reportable under Item 5.02 of Form 8-K and Item 404(a) of Regulation S-K.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

None

	PANACEA GLOBAL, INC.
Date: September 22, 2015	By:	/s/ Mahmood Moshiri
		Mahmood Moshiri Chief Executive Officer

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.






	PANACEA GLOBAL, INC.

Date: July 19, 2016	By:	/s/ Yuri Lawryshyn
		Yuri Lawryshyn Chief Executive Officer

Filing Compare · Panacea Global, Inc.